The Food and Drug Administration’s refusal to even file Moderna’s application for its first mRNA-based flu shot is more than a bureaucratic hiccup. It is a rare public rebuke of a company that helped ...

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.

Co‑injecting three common amino acids with LNPs dramatically boosted both mRNA delivery and CRISPR gene editing efficiency in preclinical models.

Add Yahoo as a preferred source to see more of our stories on Google. In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls ...

Innorna, a clinical‑stage biotech company advancing RNA medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IN026 ...

Better mRNA release inside cells boosts vaccine and gene editing performance, enabled by redesigned lipid molecules that grip ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...

SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...

The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine. The agency’s decision, which Moderna announced in a press ...